ERBB2 and breast cancer: While the direct interactions between CD200 and CDK4/6 pathways are not well documented, the preclinical evidence suggests that the immune modulation from anti-CD200 might potentiate the effects of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative breast cancers [18].